Fragile X Syndrome (FXS)- Market Insights, Epidemiology, and Market Forecast-2028
SKU ID :DEL-15122947 | Published Date: 01-Jan-2020 | No. of pages: 135Description
TOC
1. Key Insights
2. Fragile X Syndrome (FXS): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of FXS in 2017
2.2. Total Market Share (%) Distribution of FXS in 2028
3. Disease Background and Overview: Fragile X Syndrome (FXS)
3.1. Introduction
3.2. Genomics
3.3. Symptoms
3.4. Clinical Features
3.5. Diagnosis
3.6. Fragile X and Newborn Screening
3.6.1. Recommendations for Diagnostic Testing
3.6.2. Differential Diagnosis
4. Epidemiology and Patient Population: Fragile X Syndrome
4.1. Key Findings
4.2. Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM
4.3. United States
4.3.1. Assumptions and Rationale
4.3.2. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States
4.3.3. Gender-Specific Cases of Fragile X Syndrome (FXS) in the United States
4.3.4. Age-Specific Cases of Fragile X Syndrome (FXS) in the United States
4.4. EU5
4.5. Assumptions and Rationale
4.6. Germany
4.6.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Germany
4.6.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in Germany
4.6.3. Age-Specific Cases of Fragile X Syndrome (FXS) in Germany
4.7. France
4.7.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in France
4.7.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in France
4.7.3. Age-Specific Cases of Fragile X Syndrome (FXS) in France
4.8. Italy
4.8.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Italy
4.8.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in Italy
4.8.3. Age-Specific Cases of Fragile X Syndrome (FXS) in Italy
4.9. Spain
4.9.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Spain
4.9.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in Spain
4.9.3. Age-Specific Cases of Fragile X Syndrome (FXS) in Spain
4.10. United Kingdom (UK)
4.10.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome in the United Kingdom
4.10.2. Gender-Specific Cases of Fragile X Syndrome in the United Kingdom
4.10.3. Age-Specific Cases of Fragile X Syndrome (FXS) in the United Kingdom
4.11. Japan
4.11.1. Assumptions and Rationale
4.11.2. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Japan
4.11.3. Gender-Specific Cases of Fragile X Syndrome (FXS) in Japan
4.11.4. Age-Specific Cases of Fragile X Syndrome (FXS) in Japan
5. Current Treatment
6. Unmet Need
7. Emerging Drugs
7.1. Key Cross Competition
7.2. Cannabidiol: Zynerba Pharmaceuticals
7.2.1. Product Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Acamprosate: Confluence Pharmaceuticals
7.3.1. Product Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. BPN14770: Tetra Therapeutics
7.4.1. Product Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Safety and Efficacy
7.4.5. Product Profile
7.5. OV101: Ovid Therapeutics
7.5.1. Product Description
7.5.2. Other Developmental Activities
7.5.3. Clinical Development
7.5.4. Safety and Efficacy
7.5.5. Product Profile
7.6. Trofinetide: Neuren Pharmaceuticals
7.6.1. Product Description
7.6.2. Other Developmental Activities
7.6.3. Clinical Development
7.6.4. Safety and Efficacy
7.6.5. Product Profile
8. Market Size: Fragile X Syndrome
8.1. Key Findings
8.2. Total Market Size of Fragile X Syndrome in 7MM
8.3. Total Market Size of Fragile X Syndrome by Therapies in 7MM
9. Market Outlook: 7 MM
9.1. United States
9.1.1. The total market size of Fragile X Syndrome in the US
9.1.2. Total Market Size of Fragile X Syndrome by Therapies in the US
9.2. EU5
9.3. Germany
9.3.1. The total market size of Fragile X Syndrome in Germany
9.3.2. Total Market Size of Fragile X Syndrome by Therapies in Germany
9.4. France
9.4.1. The total market size of Fragile X Syndrome in France
9.4.2. Total Market Size of Fragile X Syndrome by Therapies in France
9.4.3. Italy
9.4.4. The total market size of Fragile X Syndrome in Italy
9.4.5. Total Market Size of Fragile X Syndrome by Therapies in Italy
9.5. Spain
9.5.1. The total market size of Fragile X Syndrome in Spain
9.5.2. Total Market Size of Fragile X Syndrome by Therapies in Spain
9.6. United Kingdom
9.6.1. The total market size of Fragile X Syndrome in the UK
9.6.2. Total Market Size of Fragile X Syndrome by Therapies in the UK
9.7. Japan
9.7.1. The total market size of Fragile X Syndrome in Japan
9.7.2. Total Market Size of Fragile X Syndrome by Therapies in Japan
10. Market Drivers
11. Market Barriers
12. KOL Views
13. Appendix
13.1. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
Tables & Figures
Table 1: Individuals for Whom Testing Should Be Considered for Fragile X syndrome diagnosis
Table 2: Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM (2017–2028)
Table 3: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the US (2017–2028)
Table 4: Gender-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Table 5: Age-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Table 6: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Germany (2017–2028)
Table 7: Gender-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Table 8: Age-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Table 9: Total Diagnosed Prevalent Cases of Fragile X Syndrome in France (2017–2028)
Table 10: Gender-Specific Cases of Fragile X Syndrome in France (2017–2028)
Table 11: Age-Specific Cases of Fragile X Syndrome in France (2017–2028)
Table 12: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Italy (2017–2028)
Table 13: Gender-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Table 14: Age-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Table 15: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Spain (2017–2028)
Table 16: Gender-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Table 17: Age-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Table 18: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the UK (2017–2028)
Table 19: Gender-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Table 20: Age-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Table 21: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Japan (2017–2028)
Table 22: Gender-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Table 23: Age-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Table 24: Summary of medical problems and management
Table 25:Emerging Drugs Analysis
Table 26: Cannabidiol, Clinical Trial Description, 2019
Table 27: Acamprosate, Clinical Trial Description, 2019
Table 28: BPN14770, Clinical Trial Description, 2019
Table 29: OV101, Clinical Trial Description, 2019
Table 30: Trofinetide, Clinical Trial Description, 2019
Table 31: Total Market Size of Fragile X Syndrome in 7MM in USD Million (2017-2028)
Table 32: Total Market Size of FXS by Therapies in 7MM in USD Million (2017-2028)
Table 33: Total Market size of Fragile X Syndrome in the US (2017–2028)
Table 34: Total Market Size of FXS by Therapies in the US, in USD Million (2017-2028)
Table 35: Total Market size of Fragile X Syndrome in Germany (2017–2028)
Table 36: Total Market Size of FXS by Therapies in Germany, in USD Million (2017-2028)
Table 37: Total Market size of Fragile X Syndrome in France (2017–2028)
Table 38: Total Market Size of FXS by Therapies in France, in USD Million (2017-2028)
Table 39: Total Market size of Fragile X Syndrome in Italy (2017–2028)
Table 40: Total Market Size of FXS by Therapies in Italy, in USD Million (2017-2028)
Table 41: Total Market size of Fragile X Syndrome in Spain (2017–2028)
Table 42: Total Market Size of FXS by Therapies in Spain, in USD Million (2017-2028)
Table 43: Total Market size of Fragile X Syndrome in the UK (2017–2028)
Table 44: Total Market Size of FXS by Therapies in the UK, in USD Million (2017-2028)
Table 45: Total Market size of Fragile X Syndrome in Japan (2017–2028)
Table 46: Total Market Size of FXS by Therapies in Japan, in USD Million (2017-2028)
Figure 1: The four alleles of the human FMR1 gene
Figure 2: Behavioral features of Fragile X Syndrome
Figure 3: Physical features of Fragile X Syndrome
Figure 4: Use of molecular techniques for Fragile X Syndrome (FXS) diagnosis
Figure 5: Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM (2017–2028)
Figure 6: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the US (2017–2028)
Figure 7: Gender-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Figure 8: Age-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Figure 9: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Germany (2017–2028)
Figure 10: Gender-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Figure 11: Age-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Figure 12: Total Diagnosed Prevalent Cases of Fragile X Syndrome in France (2017–2028)
Figure 13: Gender-Specific Cases of Fragile X Syndrome in France (2017–2028)
Figure 14: Age-Specific Cases of Fragile X Syndrome in France (2017–2028)
Figure 15: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Italy (2017–2028)
Figure 16: Gender-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Figure 17: Age-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Figure 18: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Spain (2017–2028)
Figure 19: Gender-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Figure 20: Age-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Figure 21: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the UK (2017–2028)
Figure 22: Gender-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Figure 23: Age-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Figure 24: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Japan (2017–2028)
Figure 25: Gender-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Figure 26: Age-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Figure 27: Unmet Need
Figure 28: Total Market Size of Fragile X Syndrome in 7MM in USD Million (2017-2028)
Figure 29: Total Market Size of FXS by Therapies in 7MM in USD Million (2017-2028)
Figure 30: Market size of Fragile X Syndrome in the US (2017–2028)
Figure 31: Total Market Size of FXS by Therapies in the US, in USD Million (2017-2028)
Figure 32: Market size of Fragile X Syndrome in Germany (2017–2028)
Figure 33: Total Market Size of FXS by Therapies in Germany, in USD Million (2017-2028)
Figure 34: Market size of Fragile X Syndrome in France (2017–2028)
Figure 35: Total Market Size of FXS by Therapies in France, in USD Million (2017-2028)
Figure 36: Market size of Fragile X Syndrome in Italy (2017–2028)
Figure 37: Total Market Size of FXS by Therapies in Italy, in USD Million (2017-2028)
Figure 38: Market size of Fragile X Syndrome in Spain (2017–2028)
Figure 39: Total Market Size of FXS by Therapies in Spain, in USD Million (2017-2028)
Figure 40: Market size of Fragile X Syndrome in the UK (2017–2028)
Figure 41: Total Market Size of FXS by Therapies in the UK, in USD Million (2017-2028)
Figure 42: Market size of Fragile X Syndrome in Japan (2017–2028)
Figure 43: Total Market Size of FXS by Therapies in Japan, in USD Million (2017-2028)
Figure 44: Market Drivers
Figure 45:Market Barriers
Companies
Tetra Therapeutics
Zynerba Pharmaceuticals
Ovid Therapeutics
Confluence Pharmaceuticals
Neuren Pharmaceuticals
- PRICE
-
$6250$18750